Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"WuXi AppTec Inc.","sponsor":"Simcha Therapeutics","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Simcha debuts with $25M to advance custom-built IL-18 for cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"STA Pharmaceutical","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"WuXi AppTec Inc.","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orbit Discovery and WuXi AppTec Sign Agreement to Access Peptide Discovery and Optimisation Technologies","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Peptide","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"WuXi AppTec Inc.","sponsor":"Sirona Biochem Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sirona Biochem Contracts WuXi AppTec to Manufacture Revolutionary Anti-Aging\/Anti-Wrinkle Compound for Clinical Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi ATU Announces Licensing Agreement with Janssen for TESSA\u2122 Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed"},{"orgOrder":0,"company":"WuXi AppTec Inc.","sponsor":"Pasithea Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Interius BioTherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by WuXi AppTec Inc.

    Menu

    WuXi AppTec Inc.

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              WuXi Advanced Therapies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201

              Details:

              Under the agreement, WuXi ATU will serve as a cell processing manufacturing partner for the planned global clinical development of CABA-201, a 4-1BB-containing fully human CD19-CAR T, in systemic lupus erythematosus and idiopathic inflammatory myopathies, or myositis.

              Lead Product(s): CABA-201

              Therapeutic Area: Immunology Product Name: CABA-201

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Cabaletta Bio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement August 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              WuXi Advanced Therapies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies

              Details:

              Through the partnership, Interius will leverage WuXi ATU's CTDMO platform for Good Manufacturing Process (GMP) manufacturing of Phase I clinical product and will advance INT-2104 in vivo CART program for B cell malignancies to the clinic.

              Lead Product(s): INT-2104

              Therapeutic Area: Oncology Product Name: INT-2104

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Interius BioTherapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 08, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              WuXi AppTec Inc.

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

              Details:

              PAS-004 (CIP-137401) is a small molecule allosteric inhibitor of MEK 1/2 in the Ras-Raf-MEK-ERK signaling pathway, which plays critical roles in the regulation of diverse cellular activities, including cell proliferation, survival, differentiation, and motility.

              Lead Product(s): CIP-137401

              Therapeutic Area: Genetic Disease Product Name: PAS-004

              Highest Development Status: IND Enabling Product Type: Small molecule

              Recipient: Pasithea Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              WuXi Advanced Therapies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology

              Details:

              Under this agreement, WuXi ATU will license to Janssen its TESSA™ technology, a high-performance system that can produce 10 times more adeno-associated viral (AAV) vectors than traditional AAV manufacturing systems.

              Lead Product(s): Aav Vectors

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement August 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              WuXi AppTec Inc.

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sirona Biochem Contracts WuXi AppTec to Manufacture Revolutionary Anti-Aging/Anti-Wrinkle Compound for Clinical Trial

              Details:

              TFC-1326 has the potential to replace or supplement dermal filler injections to treat the static wrinkles. TFC-1326 with its unique mechanism of action is revolutionary in the aesthetic skin care space.

              Lead Product(s): TFC-1326

              Therapeutic Area: Dermatology Product Name: TFC-1326

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sirona Biochem Corp

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement June 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              WuXi AppTec Inc.

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orbit Discovery and WuXi AppTec Sign Agreement to Access Peptide Discovery and Optimisation Technologies

              Details:

              Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide production and manufacturing to help its Partners obtain clinically relevant data packs and materials in a rapid time frame.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Peptide

              Partner/Sponsor/Collaborator: Orbit Discovery

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              STA Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials

              Details:

              Qualigen Therapeutics has signed a contract with STA Pharmaceutical, a subsidiary of WuXi AppTec, for GMP production of AS1411, Qualigen's lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical trials.

              Lead Product(s): AS1411

              Therapeutic Area: Infections and Infectious Diseases Product Name: AS1411

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Qualigen Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement November 05, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              WuXi AppTec Inc.

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Simcha debuts with $25M to advance custom-built IL-18 for cancer

              Details:

              Simcha’s lead program involves a customized variant of interleukin-18 (IL-18), a cytokine with potent antitumor effects, developed in the lab of Scientific Founder Aaron Ring, M.D., Ph.D., Assistant Professor of Immunobiology at the Yale School of Medicine.

              Lead Product(s): ST-067

              Therapeutic Area: Oncology Product Name: ST-067

              Highest Development Status: Preclinical Product Type: Large molecule

              Recipient: Simcha Therapeutics

              Deal Size: $25.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing June 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY